Amanote Research
Register
Sign In
Pcn170 - Cost-Effectiveness of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: A Canadian Societal Perspective
Value in Health
- United Kingdom
doi 10.1016/j.jval.2018.09.253
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Date
October 1, 2018
Authors
H. Yang
J. Zhang
M. Hampe
Publisher
Elsevier BV
Related search
Pcn177 - Cost-Effectiveness of Tisagenlecleucel for Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma : A Canadian Societal Perspective
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
CTL019 (Tisagenlecleucel): CAR-T Therapy for Relapsed and Refractory B-Cell Acute Lymphoblastic Leukemia
Drug Design, Development and Therapy
Drug Discovery
Pharmacology
Pharmaceutical Science
Cost Effectiveness of Blinatumomab Versus Inotuzumab Ozogamicin in Adult Patients With Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in the United States
PharmacoEconomics
Health Policy
Public Health
Occupational Health
Pharmacology
Environmental
Pcn142 - Cost-Effectiveness Analysis of Inotuzumab Ozogamicin for the Treatment of Adults With Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in Bulgaria
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Initial Experience With CMC-544 (Inotuzumab Ozogamicin) in Pediatric Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
Pediatric Blood and Cancer
Oncology
Child Health
Hematology
Perinatology
Medicine
Pediatrics
Pcn77 - Budget Impact Analysis of Blinatumomab for the Treatment of Pediatric Patients With Philadelphia Negative Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in Mexico
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pcn126 - Direct Cost Study of Allogeneic Hematopoietic Stem Cell Transplantation (Ahsct) for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Patients From the French Hospital Perspective
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Phase I/Ii Trial of Nanomolecular Liposomal Annamycin in Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
Clinical Lymphoma, Myeloma and Leukemia
Cancer Research
Oncology
Hematology
Phase II Study of Clofarabine in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
